These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1285 related articles for article (PubMed ID: 21715678)

  • 21. Apolipoprotein E4 influences amyloid deposition but not cell loss after traumatic brain injury in a mouse model of Alzheimer's disease.
    Hartman RE; Laurer H; Longhi L; Bales KR; Paul SM; McIntosh TK; Holtzman DM
    J Neurosci; 2002 Dec; 22(23):10083-7. PubMed ID: 12451108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human apolipoprotein E redistributes fibrillar amyloid deposition in Tg-SwDI mice.
    Xu F; Vitek MP; Colton CA; Previti ML; Gharkholonarehe N; Davis J; Van Nostrand WE
    J Neurosci; 2008 May; 28(20):5312-20. PubMed ID: 18480287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel apoE-mimetic increases brain apoE levels, reduces Aβ pathology and improves memory when treated before onset of pathology in male mice that express APOE3.
    Valencia-Olvera AC; Balu D; Bellur S; McNally T; Saleh Y; Pham D; Ghura S; York J; Johansson JO; LaDu MJ; Tai L
    Alzheimers Res Ther; 2023 Dec; 15(1):216. PubMed ID: 38102668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis.
    Castellano JM; Deane R; Gottesdiener AJ; Verghese PB; Stewart FR; West T; Paoletti AC; Kasper TR; DeMattos RB; Zlokovic BV; Holtzman DM
    Proc Natl Acad Sci U S A; 2012 Sep; 109(38):15502-7. PubMed ID: 22927427
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endogenous Apolipoprotein E (ApoE) Fragmentation Is Linked to Amyloid Pathology in Transgenic Mouse Models of Alzheimer's Disease.
    Saul A; Wirths O
    Mol Neurobiol; 2017 Jan; 54(1):319-327. PubMed ID: 26742512
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ApoE-isoform-dependent cellular uptake of amyloid-β is mediated by lipoprotein receptor LR11/SorLA.
    Yajima R; Tokutake T; Koyama A; Kasuga K; Tezuka T; Nishizawa M; Ikeuchi T
    Biochem Biophys Res Commun; 2015 Jan; 456(1):482-8. PubMed ID: 25482438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Co-aggregation with Apolipoprotein E modulates the function of Amyloid-β in Alzheimer's disease.
    Xia Z; Prescott EE; Urbanek A; Wareing HE; King MC; Olerinyova A; Dakin H; Leah T; Barnes KA; Matuszyk MM; Dimou E; Hidari E; Zhang YP; Lam JYL; Danial JSH; Strickland MR; Jiang H; Thornton P; Crowther DC; Ohtonen S; Gómez-Budia M; Bell SM; Ferraiuolo L; Mortiboys H; Higginbottom A; Wharton SB; Holtzman DM; Malm T; Ranasinghe RT; Klenerman D; De S
    Nat Commun; 2024 Jun; 15(1):4695. PubMed ID: 38824138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic associations between cathepsin D exon 2 C-->T polymorphism and Alzheimer's disease, and pathological correlations with genotype.
    Davidson Y; Gibbons L; Pritchard A; Hardicre J; Wren J; Tian J; Shi J; Stopford C; Julien C; Thompson J; Payton A; Thaker U; Hayes AJ; Iwatsubo T; Pickering-Brown SM; Pendleton N; Horan MA; Burns A; Purandare N; Lendon CL; Neary D; Snowden JS; Mann DM
    J Neurol Neurosurg Psychiatry; 2006 Apr; 77(4):515-7. PubMed ID: 16543533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apolipoprotein E level and cholesterol are associated with reduced synaptic amyloid beta in Alzheimer's disease and apoE TR mouse cortex.
    Arold S; Sullivan P; Bilousova T; Teng E; Miller CA; Poon WW; Vinters HV; Cornwell LB; Saing T; Cole GM; Gylys KH
    Acta Neuropathol; 2012 Jan; 123(1):39-52. PubMed ID: 22020632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. APOE4-mediated amyloid-β pathology depends on its neuronal receptor LRP1.
    Tachibana M; Holm ML; Liu CC; Shinohara M; Aikawa T; Oue H; Yamazaki Y; Martens YA; Murray ME; Sullivan PM; Weyer K; Glerup S; Dickson DW; Bu G; Kanekiyo T
    J Clin Invest; 2019 Mar; 129(3):1272-1277. PubMed ID: 30741718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantification of total apolipoprotein E and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases.
    Minta K; Brinkmalm G; Janelidze S; Sjödin S; Portelius E; Stomrud E; Zetterberg H; Blennow K; Hansson O; Andreasson U
    Alzheimers Res Ther; 2020 Feb; 12(1):19. PubMed ID: 32054532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
    Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
    Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease.
    Dodart JC; Marr RA; Koistinaho M; Gregersen BM; Malkani S; Verma IM; Paul SM
    Proc Natl Acad Sci U S A; 2005 Jan; 102(4):1211-6. PubMed ID: 15657137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular pathogenesis of apolipoprotein E-mediated amyloidosis in late-onset Alzheimer's disease.
    Tomiyama T; Corder EH; Mori H
    Cell Mol Life Sci; 1999 Oct; 56(3-4):268-79. PubMed ID: 11212354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lack of hepatic apoE does not influence early Aβ deposition: observations from a new APOE knock-in model.
    Huynh TV; Wang C; Tran AC; Tabor GT; Mahan TE; Francis CM; Finn MB; Spellman R; Manis M; Tanzi RE; Ulrich JD; Holtzman DM
    Mol Neurodegener; 2019 Oct; 14(1):37. PubMed ID: 31623648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aging, gender and APOE isotype modulate metabolism of Alzheimer's Abeta peptides and F-isoprostanes in the absence of detectable amyloid deposits.
    Yao J; Petanceska SS; Montine TJ; Holtzman DM; Schmidt SD; Parker CA; Callahan MJ; Lipinski WJ; Bisgaier CL; Turner BA; Nixon RA; Martins RN; Ouimet C; Smith JD; Davies P; Laska E; Ehrlich ME; Walker LC; Mathews PM; Gandy S
    J Neurochem; 2004 Aug; 90(4):1011-8. PubMed ID: 15287908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. APOE genotype results in differential effects on the peripheral clearance of amyloid-beta42 in APOE knock-in and knock-out mice.
    Sharman MJ; Morici M; Hone E; Berger T; Taddei K; Martins IJ; Lim WL; Singh S; Wenk MR; Ghiso J; Buxbaum JD; Gandy S; Martins RN
    J Alzheimers Dis; 2010; 21(2):403-9. PubMed ID: 20555142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The interaction of amyloid-beta with ApoE.
    Carter DB
    Subcell Biochem; 2005; 38():255-72. PubMed ID: 15709483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-ApoE antibody given after plaque onset decreases Aβ accumulation and improves brain function in a mouse model of Aβ amyloidosis.
    Liao F; Hori Y; Hudry E; Bauer AQ; Jiang H; Mahan TE; Lefton KB; Zhang TJ; Dearborn JT; Kim J; Culver JP; Betensky R; Wozniak DF; Hyman BT; Holtzman DM
    J Neurosci; 2014 May; 34(21):7281-92. PubMed ID: 24849360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice.
    Sadowski M; Pankiewicz J; Scholtzova H; Ripellino JA; Li Y; Schmidt SD; Mathews PM; Fryer JD; Holtzman DM; Sigurdsson EM; Wisniewski T
    Am J Pathol; 2004 Sep; 165(3):937-48. PubMed ID: 15331417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 65.